Why in news
- National Pharmaceutical Pricing Authority capped trade margins on Maximum Retail Price for 137 anti-cancer drugs.
- The revision covers over 1,000 formulations, significantly reducing out-of-pocket costs for cancer patients.
Key terms
NPPA
Independent pharmaceutical price regulator under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Trade Margin Rationalization
Capping the difference between the price at which a manufacturer sells to trade and the final MRP.
Non-scheduled Drugs
Medicines not listed under National List of Essential Medicines whose prices are monitored rather than directly fixed.
DPCO 2013
Drugs (Prices Control) Order issued under Essential Commodities Act empowering government to regulate drug prices.
What is Trade Margin Rationalization (TMR)?
- TMR is a policy mechanism to cap the price mark-ups charged by trade channels (distributors and retailers) between stockist price and MRP.
- It is applied to non-scheduled drugs that do not fall under direct ceiling price control under Drugs (Prices Control) Order (DPCO).
- Imposed by NPPA under powers conferred by Para 19 of the DPCO 2013 in public interest.
Key provisions of the order
- Caps trade margins on 137 identified anti-cancer formulations based on DGHS expert committee recommendations.
- Covers both existing marketed formulations and prospective drugs launched in the future.
- Mandates manufacturers and trade channels to pass price reductions directly to retail consumers.
Why it matters
- Curbing exorbitant trade mark-ups directly mitigates catastrophic out-of-pocket healthcare expenditure for critical care.
- Strikes a balance between pharmaceutical innovation incentives and public health affordability.
Prelims facts
- NPPA operates under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Trade Margin Rationalization targets non-scheduled medicines to prevent unreasonable trade mark-ups.
Mains discussion
- Role of Trade Margin Rationalization in addressing catastrophic health expenditures in India.
- Evaluating the regulatory balance between drug affordability and pharmaceutical market incentives.
Source: PIB
Same topic · past papers
UPSC has asked this before
These previous-year questions sit on the same topic. Open one to practise the earlier ask.